Clinical trial helps man with leukemia live decades longer
Melvin Mann, diagnosed with chronic myeloid leukemia in 1994, participated in a clinical trial for Imatinib that extended his ...
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...
Bio-Path provides key clinical updates on BP1001-A, AML
Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and ...
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today ...
Oral arsenic trioxide for leukemia has a 97% cure rate: Hong Kong's prescription medicine enters international arena
Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...
Victoria News14h
$6.8M campaign will play critical role in Victoria cancer centre research
The BC Cancer Foundation is looking to raise $6.8 million to expand its provincial immunotherapy research program, a ...
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...
Investornewsbreaks TC Biopharm Holdings PLC (NASDAQ: TCBP) Completes Dosing In Phase 2B AML Trial, Reports Positive Early Data
TC BioPharm (NASDAQ: TCBP) announced the completion of patient dosing in Cohort A of its ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 for re ...
TC BioPharm: TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
No adverse events related to TCB008 have occurred Evidence of stable disease following TCB008 infusion EDINBURGH, Scotland, Feb. 13, 2025 /PRNewswire/ -- TC ...
Healthline9d
What Are the Latest Treatment Options for Chronic Myeloid Leukemia (CML)?
Researchers are exploring new treatment options for chronic myeloid leukemia (CML ... Dasatinib is another TKI targeted therapy drug. Clinical trials are studies comparing new treatments to ...